AG
ACHN

Advisor Group’s Achillion Pharmaceuticals ACHN Stock Holding History

Advisor Group’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$1K Hold
87
– – ﹤0.01% 5269
2019
Q3 		$0 Hold
87
– – ﹤0.01% 5539
2019
Q2 		$0 Hold
87
– – ﹤0.01% 5483
2019
Q1 		$0 Hold
87
– – ﹤0.01% 5417
2018
Q4 		$0 Hold
87
– – ﹤0.01% 5347
2018
Q3 		$0 Hold
87
– – ﹤0.01% 5318
2018
Q2 		$0 Hold
87
– – ﹤0.01% 5130
2018
Q1 		$0 Sell
87
-200
-70% -$655 ﹤0.01% 5150
2017
Q4 		$1K Hold
287
– – ﹤0.01% 4904
2017
Q3 		$1K Hold
287
– – ﹤0.01% 4774
2017
Q2 		$1K Sell
287
-1,500
-84% -$6.03K ﹤0.01% 4729
2017
Q1 		$7K Sell
1,787
-400
-18% -$1.66K ﹤0.01% 3999
2016
Q4 		$9K Buy
2,187
+1,100
+101% +$5.85K ﹤0.01% 3693
2016
Q3 		$9K Buy
1,087
+487
+81% +$4.14K ﹤0.01% 3645
2016
Q2 		$4K Buy
+600
New +$5.15K ﹤0.01% 3914

Other funds holding ACHN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Advisor Group's ACHN Position: Q4 2019 in Review

Advisor Group held its Achillion Pharmaceuticals (ACHN) position steady in Q4 2019 at 87 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #5269.

Advisor Group first reported a position in ACHN in Q2 2016 and has held it in 15 quarters since. The position peaked at $9K in Q4 2016. 132 funds tracked by Wall St. Rank hold ACHN as of Q4 2019.

  • Advisor Group held 87 shares of Achillion Pharmaceuticals worth $1K as of Q4 2019.
  • Advisor Group left its Achillion Pharmaceuticals share count unchanged in Q4 2019.
  • Achillion Pharmaceuticals made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5269 holding.
  • Advisor Group first reported a position in Achillion Pharmaceuticals in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's Achillion Pharmaceuticals position peaked at $9K in Q4 2016.
  • 132 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.